What's happening with the CSL (ASX:CSL) share price?

The CSL Limited (ASX: CSL) share price has been under pressure over the past number of months. We take a closer look at the blue-chip share.

The CSL Limited (ASX: CSL) share price has been under pressure over the past number of months. This comes despite the company continuing to perform its business operations with COVID-19 in the background.

Since late November, the global biotech's shares have fallen around 16% in value. Today, CSL shares can be picked up for $266.67 apiece at the time of writing. This reflects an attractive discount for a quality blue-chip company.

Below, we take a look at 3 reasons why the CSL share price could be good value today.

Impeccable growth track record

While CSL shares might be temporarily down from their 2020 highs, the company has been around since 1916. Formerly known as Commonwealth Serum Laboratories, CSL has grown from a small-cap stock to become a global biotherapeutics and vaccine company.

With more than 1,700 scientists working across the world, this biotech behemoth specialises in developing and delivering plasma-derived products for treating serious and rare diseases, as well as being one of the largest influenza vaccine providers.

In its most recent financial report, CSL recorded $5,739 million in revenue, which amounted to a 15% increase over H1 FY21.

To put into perspective how large the company has grown over time, CSL reported $3,056 million in revenue from 5 years ago (H1 FY16). That's almost double the revenue in just a few short years of the company's long history.

COVID-19 will pass

No one could have foreseen what 2020 would behold with COVID-19 severely impacting the global economy and affecting everyday lives.

More than  128 million people have been confirmed to have been infected with the virus, representing almost 2% of the entire world population. Although the World Health Organisation said that best estimates indicate roughly 1 in 10 people worldwide may have had the virus.

As the worst may be over with pharmaceutical companies rolling out vaccines hastily to governments, COVID-19 is expected to subside. Experts predict that social norms will gradually return sometime in late 2021 to early 2022.

This could mean that CSL will see its plasma collections return to normal levels as well as the resumption of postponed R&D programs. The company traditionally uses its free cash flow amounts to drive growth through funding its R&D division.

CSL share price weakness

CSL shares have been treading lower in the past year, now trading at almost the same price as recorded in November 2019. The company momentarily reached a high of $320.42 in late November 2020 before trending downwards from there.

The CSL share price hit a 52-week low of $242.00 earlier this month and appears to have bottomed out. Since then, its shares have been on an upwards trajectory.

As one of the ASX market's largest companies in terms of market capitalisation, the CSL share price is valued at $119.5 billion. Furthermore, the company has more than 455 million shares on issue.

Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »